Keyword: Teva Pharmaceutical
A physician survey suggests new drugs to treat tardive dyskinesia—Neurocrine’s Ingrezza, in particular—may capture sales that beat current expectations.
Novo has filed a citizen petition saying Victoza’s manufacturing is so complex that equivalence of generics can't be certain without clinical trials.
On Monday, one analyst offered a window into how pricing is playing out so far with Mylan's Copaxone generic.
Just two days after Mylan won FDA approval for its long-acting Copaxone generic, Mylan’s European partner got a green light, too.
Mylan’s long been frustrated by generics delays. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense.
Impax Labs CEO Paul Bisaro, who has extensive experience building companies through M&A, is reportedly in talks with competitor Amneal.
After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing practices.
Kåre Schultz has yet to take over at beleaguered Teva, but he is already getting advice on what to do from some of this investors.
Bracing for generic rivals to its top-selling Advair—and looking to fill the sales gap—GSK nabbed FDA approval for its new respiratory med, Trelegy.
Teva unveiled terms to sell its remaining women's health products, gaining $1.38 billion that'll go toward paying down debt.